RT Journal Article
SR Electronic
T1 Respiratory syncytial virus-associated hospital admissions by deprivation levels among children and adults in Scotland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.15.23294119
DO 10.1101/2023.08.15.23294119
A1 Osei-Yeboah, Richard
A1 Zhu, Fuyu
A1 Wang, Xin
A1 Nair, Harish
A1 Campbell, Harry
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.08.15.23294119.abstract
AB Background Socioeconomic deprivation may predispose individuals to respiratory tract infections (RTI). We aimed to estimate the number and rate of RSV-associated hospitalisations by socioeconomic status using the Scottish Index of Multiple Deprivation (SIMD).Methods Using national routine healthcare records and virological surveillance from 2010-2016, we used a time-series linear regression model and a direct measurement based on ICD-10 coded diagnoses to estimate RSV-associated hospitalisations by SIMD level and age and compared to influenza-associated hospitalisations.Results Using the model-based approach, we estimated an annual average rate per 1000 of 0.76 (95%CI: 0.43-0.90) for individuals of all ages in the least deprived group (5th quintile of SIMD) to 1.51 (1.03-1.79) for the most deprived group (1st quintile). Compared with the least deprived group, we estimated that the rate ratio (RR) was 1.96 (95%CI: 1.23-3.25), 1.60 (1.0- 2.66), 1.35 (0.85-2.25), and 1.12 (0.7-1.85) in the 1st to 4th quintile. The pattern of RSV- associated RTI hospitalisation rates variation with SIMD was most pronounced in children aged 2 years and below. The ICD-10 direct measurement approach provided much lower rates than the model-based approach but yielded similar RR estimates between SIMD groups.Conclusion Higher RSV hospitalisation rates are seen in the Scottish population of higher deprived levels. The differences between deprivation levels are most pronounced in infants and young children.Competing Interest StatementHC reports grants, personal fees, and nonfinancial support from World Health Organization, grants and personal fees from Sanofi Pasteur, grants from Bill and Melinda Gates Foundation, outside this submitted work. HC is a shareholder in the Journal of Global Health Ltd. HN reports grants from Pfizer, Icosavax, consulting fees from WHO, Pfizer, Bill and Melinda Gates Foundation, Abbvie and Sanofi, outside the submitted work. HN reports participation on a Data Safety Monitoring Board or Advisory Board of GSK, Sanofi, Merck, WHO, Janssen, Novavax, Resvinet, Icosavax and Pfizer. XW reports grants from GlaxoSmithKline and consultancy fees from Pfizer, outside the submitted work. All other authors report no potential conflicts.Funding StatementThis work is part of PROMISE and has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034339 as well as from Nanjing Medical University Talents Start-up Grants (Grant number NMUR20210009). The Innovative Medicines Initiative 2 Joint Undertaking receives support from the European Union Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and AssociationsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Request to access patient records was approved by the Health and Social Sciences Public Benefit and Privacy Panel of Scotland. The data used in this study was provided by the electronic data research and innovation services team at Public Health Scotland.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript. Request for these data may be made to the electronic data research and innovation services (eDRIS) team at Public Health Scotland